We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cannabis Stock ACB Down 19% YTD: Should You Buy the Dip?
Read MoreHide Full Article
Key Takeaways
ACB shares are down 19% YTD, underperforming the cannabis industry's 15% decline.
Aurora Cannabis is leaning on medical cannabis, with revenues up ~20% to C$211.5M in nine months.
Aurora Cannabis is scaling back consumer cannabis amid pricing pressure and intensifying competition.
Shares of Aurora Cannabis (ACB - Free Report) have lost 19% year to date compared with the industry‘s 15% decline, as shown in the chart below.
Image Source: Zacks Investment Research
The underperformance reflects a mix of sector-wide pressures and company-specific positioning. While intensifying competition in Canada’s mature cannabis market continues to weigh on Aurora Cannabis’ growth prospects, its limited presence in the United States has also constrained its ability to capitalize on recent cannabis-related policy momentum.
Let’s delve into the company’s fundamentals to better assess the stock following the decline.
Medical Cannabis Remains Aurora Cannabis’ Core Growth Engine
Aurora Cannabis continues to anchor its growth strategy around global medical cannabis, which remains the primary driver of both revenue and profitability. The segment has delivered consistent momentum, supported by strong demand across key international markets and a disciplined focus on higher-margin products.
For the nine months of fiscal 2026 (year ended March 2026), medical cannabis revenues increased about 20% year over year to C$211.5 million, accounting for nearly 75% of total sales. Growth was driven by increasing contributions from international markets, such as Germany, Australia and Poland, alongside steady demand in Canada from both insurance-covered and self-paying patients.
The strength of this segment is also evident in its margin profile. Higher-margin international sales, favorable product mix and ongoing production efficiencies have supported margin expansion through most of the fiscal year, with profitability levels stabilizing in the most recent quarter. This has translated into meaningful operating leverage, with adjusted EBITDA rising 35% year over year to about C$45 million for the nine months ended December 2025.
Aurora Cannabis’ latest updates further reinforce this trajectory. Management continues to prioritize international medical markets, where regulatory frameworks, pricing stability and demand visibility are more favorable compared to the recreational segment. The company is actively aligning its operations and capital allocation toward these markets, while streamlining lower-return activities to enhance overall profitability.
Aurora Cannabis expects global medical cannabis to remain its primary growth engine. The company expects fiscal 2026 medical cannabis revenues to be in the range of C$269-C$281 million, representing 10-15% year-over-year growth, supported by continued international expansion, new product launches and scaling in key European markets. Adjusted EBITDA is expected to reach C$52-C$57 million, with the company maintaining positive free cash flow as efficiencies improve.
ACB’s Consumer Cannabis Takes a Back Seat
Aurora Cannabis’ consumer cannabis business continues to weaken, reflecting structural challenges in Canada’s oversupplied adult-use market. Persistent price compression and aggressive competition have eroded both revenue potential and margins, making the segment increasingly unattractive relative to the company’s medical operations.
As a result, Aurora is now actively repositioning away from this segment. The company is scaling back participation in lower-margin consumer markets in Canada and redirecting capital and operational focus toward its higher-margin global medical cannabis platform. This shift highlights ACB’s effort to prioritize segments with stronger pricing power, more predictable demand and better long-term returns.
The strategic pullback is also expected to streamline Aurora’s cost structure. Management has indicated that reducing exposure to consumer cannabis should lower sales and marketing expenses and support consolidated margin expansion over time. However, the transition is not without near-term friction, with one-time costs expected to impact cash flow in the fourth quarter of fiscal 2026.
Intensifying Competition
Aurora Cannabis operates in an increasingly competitive global cannabis market, facing established players, such as Curaleaf Holdings (CURLF - Free Report) and Tilray Brands (TLRY - Free Report) . With most Canadian and international cannabis producers targeting a limited set of high-growth markets, competitive intensity remains elevated and could constrain ACB’s ability to sustain outsized market share gains.
This pressure is particularly pronounced in international markets, such as Europe, where Aurora Cannabis is focusing on its expansion strategy. Peers like Curaleaf and Tilray are also scaling their presence in these regions, increasing competition in the very markets expected to drive the company’s future growth. As a result, while international expansion offers meaningful opportunities, it also introduces execution risk and may limit pricing power over time.
ACB Valuation Estimates
Estimate movements for fiscal 2026 and 2027 have remained unchanged over the past 60 days.
Image Source: Zacks Investment Research
How to Play ACB Stock?
Aurora Cannabis has made meaningful progress in repositioning its business, with medical cannabis emerging as a key growth driver and profitability improving. The company’s expanding footprint in international markets provides a pathway to offset structural challenges in Canada’s mature recreational market.
However, the investment case remains balanced. Persistent pricing pressure, ongoing weakness in the consumer cannabis segment and restructuring-related costs continue to weigh on near-term visibility. At the same time, rising competition in international markets could limit Aurora’s ability to fully capitalize on its medical cannabis momentum. Consistent earnings estimates suggest that the recent strategic progress is not yet translating into upward revisions, indicating limited near-term upside potential.
ACB currently carries a Zacks Rank #3 (Hold), which suggests that investors may be better off waiting for clearer signs of sustained earnings growth or improved industry conditions before building meaningful positions.
View the Zacks #1 Rank List
Image: Bigstock
Cannabis Stock ACB Down 19% YTD: Should You Buy the Dip?
Key Takeaways
Shares of Aurora Cannabis (ACB - Free Report) have lost 19% year to date compared with the industry‘s 15% decline, as shown in the chart below.
Image Source: Zacks Investment Research
The underperformance reflects a mix of sector-wide pressures and company-specific positioning. While intensifying competition in Canada’s mature cannabis market continues to weigh on Aurora Cannabis’ growth prospects, its limited presence in the United States has also constrained its ability to capitalize on recent cannabis-related policy momentum.
Let’s delve into the company’s fundamentals to better assess the stock following the decline.
Medical Cannabis Remains Aurora Cannabis’ Core Growth Engine
Aurora Cannabis continues to anchor its growth strategy around global medical cannabis, which remains the primary driver of both revenue and profitability. The segment has delivered consistent momentum, supported by strong demand across key international markets and a disciplined focus on higher-margin products.
For the nine months of fiscal 2026 (year ended March 2026), medical cannabis revenues increased about 20% year over year to C$211.5 million, accounting for nearly 75% of total sales. Growth was driven by increasing contributions from international markets, such as Germany, Australia and Poland, alongside steady demand in Canada from both insurance-covered and self-paying patients.
The strength of this segment is also evident in its margin profile. Higher-margin international sales, favorable product mix and ongoing production efficiencies have supported margin expansion through most of the fiscal year, with profitability levels stabilizing in the most recent quarter. This has translated into meaningful operating leverage, with adjusted EBITDA rising 35% year over year to about C$45 million for the nine months ended December 2025.
Aurora Cannabis’ latest updates further reinforce this trajectory. Management continues to prioritize international medical markets, where regulatory frameworks, pricing stability and demand visibility are more favorable compared to the recreational segment. The company is actively aligning its operations and capital allocation toward these markets, while streamlining lower-return activities to enhance overall profitability.
Aurora Cannabis expects global medical cannabis to remain its primary growth engine. The company expects fiscal 2026 medical cannabis revenues to be in the range of C$269-C$281 million, representing 10-15% year-over-year growth, supported by continued international expansion, new product launches and scaling in key European markets. Adjusted EBITDA is expected to reach C$52-C$57 million, with the company maintaining positive free cash flow as efficiencies improve.
ACB’s Consumer Cannabis Takes a Back Seat
Aurora Cannabis’ consumer cannabis business continues to weaken, reflecting structural challenges in Canada’s oversupplied adult-use market. Persistent price compression and aggressive competition have eroded both revenue potential and margins, making the segment increasingly unattractive relative to the company’s medical operations.
As a result, Aurora is now actively repositioning away from this segment. The company is scaling back participation in lower-margin consumer markets in Canada and redirecting capital and operational focus toward its higher-margin global medical cannabis platform. This shift highlights ACB’s effort to prioritize segments with stronger pricing power, more predictable demand and better long-term returns.
The strategic pullback is also expected to streamline Aurora’s cost structure. Management has indicated that reducing exposure to consumer cannabis should lower sales and marketing expenses and support consolidated margin expansion over time. However, the transition is not without near-term friction, with one-time costs expected to impact cash flow in the fourth quarter of fiscal 2026.
Intensifying Competition
Aurora Cannabis operates in an increasingly competitive global cannabis market, facing established players, such as Curaleaf Holdings (CURLF - Free Report) and Tilray Brands (TLRY - Free Report) . With most Canadian and international cannabis producers targeting a limited set of high-growth markets, competitive intensity remains elevated and could constrain ACB’s ability to sustain outsized market share gains.
This pressure is particularly pronounced in international markets, such as Europe, where Aurora Cannabis is focusing on its expansion strategy. Peers like Curaleaf and Tilray are also scaling their presence in these regions, increasing competition in the very markets expected to drive the company’s future growth. As a result, while international expansion offers meaningful opportunities, it also introduces execution risk and may limit pricing power over time.
ACB Valuation Estimates
Estimate movements for fiscal 2026 and 2027 have remained unchanged over the past 60 days.
Image Source: Zacks Investment Research
How to Play ACB Stock?
Aurora Cannabis has made meaningful progress in repositioning its business, with medical cannabis emerging as a key growth driver and profitability improving. The company’s expanding footprint in international markets provides a pathway to offset structural challenges in Canada’s mature recreational market.
However, the investment case remains balanced. Persistent pricing pressure, ongoing weakness in the consumer cannabis segment and restructuring-related costs continue to weigh on near-term visibility. At the same time, rising competition in international markets could limit Aurora’s ability to fully capitalize on its medical cannabis momentum. Consistent earnings estimates suggest that the recent strategic progress is not yet translating into upward revisions, indicating limited near-term upside potential.
ACB currently carries a Zacks Rank #3 (Hold), which suggests that investors may be better off waiting for clearer signs of sustained earnings growth or improved industry conditions before building meaningful positions.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.